HRQoL Evaluation of Pediatric Osteogenesis Imperfecta with Zoledronic Acid Therapy
Background: Zoledronic acid, a bisphosphonate, increases bone mineral density (BMD), which can reduce clinical manifestations in osteogenesis imperfecta. This study investigates the impact of zoledronic acid therapy on the quality of life of pediatric patients with osteogenesis imperfecta. Methods:...
Saved in:
Main Authors: | Tri Wahyu Martanto, Hamzah Rafly Rahman, Patricia Maria Kurniawati |
---|---|
Format: | Article |
Language: | English |
Published: |
Universitas Airlangga
2023-10-01
|
Series: | Journal Orthopaedi and Traumatology Surabaya |
Subjects: | |
Online Access: | https://e-journal.unair.ac.id/JOINTS/article/view/48362 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Modern classification and molecular-genetic aspects of osteogenesis imperfecta
by: A. R. Zaripova, et al.
Published: (2020-04-01) -
Challenges in managing osteogenesis imperfecta in a resource-limited setting: a case report
by: Ssekabembe Richard, et al.
Published: (2025-01-01) -
Bone cell differentiation and mineralization in wild-type and osteogenesis imperfecta zebrafish are compromised by per- and poly-fluoroalkyl substances (PFAS)
by: Francesca Tonelli, et al.
Published: (2025-01-01) -
Mastication and electrical activation in the masseter and anterior temporalis muscles of children and adolescents with osteogenesis imperfecta
by: Andressa Colares da Costa Otavio, et al.
Published: (2025-01-01) -
Crystal bones. A case report
by: Alexander Torres Molina
Published: (2010-08-01)